Atropina (atropine) sulfate eye drops 1% 5 ml. vial

$9.00

Manufacturer: Ukraine

During an eye exam, the doctor may use eye drops to make the pupils bigger in order to better examine the back of the eye. This can also help determine the actual strength of the eye’s focusing power. It is also used as part of treatment for certain eye conditions like inflammation, injury, blood clots, and spasms.

Category:

Description

Ingredients

Active substance: atropine; 1 ml of atropine sulfate 10 mg
excipients: sodium metabisulfite (E 223), sodium chloride, purified water.

Medicinal form

Eye drops.

Main physical and chemical properties:  transparent colorless liquid.

Pharmacological group

Means that affect the senses. Mydriatic and cycloplegic agents. Code ATX S01F A01.

Pharmacological properties

Pharmacodynamics

Atropine sulfate reduces the secretion of salivary and other glands, causes tachycardia, improves AV conduction, reduces the tone of the smooth muscles of the organs, significantly expands the pupil (at the same time, an increase in intraocular pressure is possible), causes paralysis of accommodation.

The mechanism of action is caused by the selective blockade of m-cholinergic receptors by atropine (to a lesser extent affects n-cholinergic receptors), as a result of which the latter become insensitive to acetylcholine, which is formed in the region of the endings of postganglionic parasympathetic nerves. The ability of atropine to bind to cholinergic receptors is explained by the presence of a fragment in its molecule that gives it affinity with the molecule of the endogenous ligand – acetylcholine. The pupil is dilated by atropine and not narrowed by the instillation of cholinomimetic agents. Maximum mydriasis occurs after 30-40 minutes and lasts for 7-10 days, paralysis of accommodation, respectively, after 1-3 hours and lasts for 8-12 days.
The systemic effect of atropine is due to its anticholinergic (cholinelytic) effect, which is manifested in the suppression of salivary secretion of the gastric bronchial sweat glands of the pancreas, with increased heart rate (the inhibitory effect of the vagus nerve on the heart decreases, and a decrease in the tone of the smooth muscles of the organs).

Penetrating through the blood-brain barrier, atropine affects the central nervous system. The drug reduces muscle tone and tremors in patients with parkinsonism (central cholinolytic effect). In therapeutic doses, atropine stimulates the respiratory center. Large doses of atropine cause motor and mental disorders, convulsions, hallucinatory phenomena, respiratory paralysis.

Indication

During an eye exam, the doctor may use eye drops to make the pupils bigger in order to better examine the back of the eye. This can also help determine the actual strength of the eye’s focusing power. It is also used as part of treatment for certain eye conditions like inflammation, injury, blood clots, and spasms.

Contraindication

Contraindication. Increased sensitivity to the components of the drug.
Diseases of the cardiovascular system in which an increase in heart rate may be undesirable: atrial fibrillation, tachycardia; chronic heart failure; coronary heart disease; mitral stenosis; severe arterial hypertension. Acute bleeding. Thyrotoxicosis. Hyperthermic syndrome. Diseases of the gastrointestinal tract accompanied by obstruction (achalasia of the esophagus, stenosis of the portal vein, intestinal atony). Glaucoma. Liver and kidney failure. Myasthenia gravis. Urinary retention or tendency to it. Brain damage.

Interaction with other drugs and other types of interactions
When using atropine sulfate together with MAO inhibitors, heart rhythm disturbances occur; with quinidine novocainamide – potentiation of the cholinolytic effect is observed.

When used with preparations of lily of the valley with tannin, a physicochemical interaction is observed, which leads to a mutual weakening of the effects.
Atropine sulfate reduces the duration and depth of action of narcotics, weakens the analgesic effect of opiates.

With simultaneous use with diphenhydramine or diprazine, the effect of atropine increases with nitrates, haloperidol, glucocorticoids for systemic use – the likelihood of increased intraocular pressure increases with sertraline – the depressive effect of both drugs increases with spironolactone, minoxidil – the effect of spironolactone and minoxidil with penicillins decreases, the effect of nizatidine ketoconazole increases – the absorption of ketoconazole decreases with ascorbic acid and attapulgite – reduces the effect of atropine with pilocarpine – reduces the effect of pilocarpine in the treatment of glaucoma with oxprenolone – reduces the antihypertensive effect of the drug. Under the influence of Octadin, it is possible to reduce the hyposecretory effect of atropine, which weakens the effect of M-cholinemimetics and anticholinesterase agents.

The effect of atropine sulfate can be enhanced with the simultaneous use of other drugs with an antimuscarinic effect, M-cholinergic blockers, antiparkinsonian drugs (amantadine), antispasmodics, some antihistamines, drugs of the butyrophenone group, phenothiazines, dispyramides, quinidine, and nonselective tricyclic antidepressants.

Suppression of peristalsis under the influence of atropine can lead to changes in the absorption of other drugs.

Method of application and dosage

For therapeutic purposes, adults and children older than 7 years should be prescribed 1-2 drops 2-6 times a day. The maximum dilation of the pupils by atropine, which helps to relax the eye muscles and accelerates the regression of the pathological process, is observed after 30-40 minutes and persists for 7-10 days; paralysis of accommodation – respectively, after 1-3 hours and persists for 8-12 days.